논문실적
Home › 연구실적 › 논문실적
- 350Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: A population pharmacokinetics study on a large prospective cohort
Hung TM, Jayanti RP, Lee HY, Kim HJ, Mok JH, Jang TW, Oh JY, Kim JS, Ko YS, Min JS, Hoa PQ, Ahn SZ, Long NP, Cho YS, Shin JG, cPMTb · Int J Antimicrob Agents. 62(2):106840 / 2023.08 · 2023 cPMTb
- 349Multimodal plasma metabolomics and lipidomics in elucidating metabolic perturbations in tuberculosis patients with concurrent type 2 diabetes
Yen NTH, Anh NK, Jayanti RP, Phat NK, Vu DH, Ghim JL, Ahn SZ, Shin JG, Oh JY, Long NP, Kim DH · Biochimie. 211:153-163 / 2023.08 · 2023 cPMTb
- 348Lipid class-dependent alterations of Caenorhabditis elegans under harmane exposure
Nguyen BT, Yen NTH, Tung NKT, Jeong GS, Kang JS, Long NP, Kim HM · J Pharm Biomed Anal. 5:231:115401 / 2023.07 · 2023 cPMTb
- 347Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
Oh MK, Lee HC, Kim SU, Kim BT, Song GS, Shin JG, Ghim JL · Transl Clin Pharmacol. 31(2):114-123 / 2023.06 · 2023 cPMTb
- 346Impact of Criterion Versus Norm-Referenced Assessment on the Quality of Life in Korean Medical Students
Park CH, Kwon JH, Lee JT, Ahn SZ · J Korean Med Sci. 38(17):e133 / 2023.05 · 2023 cPMTb
- 345Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance
Kim RH, Jayanti RP, Lee HY, Kim HK, Kang JY, Park IN, Kim JH, Oh JY, Kim HW, Lee HY, Ghim JL, Ahn SZ, Long NP, Cho YS, Shin JG, On Behalf Of The cPMTb · Front Pharmacol. 26:14:1116226 / 2023.05 · 2023 cPMTb
- 344Pharmacokinetic Interactions Between Bazedoxifene and Cholecalciferol: An Open-Label, Randomized, Crossover Study in Healthy Male Volunteers
Lee MH, Yoon SK, Kim HS, Cho YS, Han SP, Lee SH, Bae KS, Jung JN, Hong SH, Lim HS · Drug Des Devel Ther. 12:17:1107-1114 / 2023.04 · 2023 cPMTb
- 343Systems-level multi-omics characterization provides novel molecular insights into indomethacin toxicity
Yen NTH, Oh JH, Anh NTV, Le QV, Park SM, Park YJ, Cho YS, Moon KS, Nguyen HT, Shin JG, Long NP · Chem Biol Interact. 25:375:110430 / 2023.04 · 2023 cPMTb
- 342CYP2C19 Contributes to THP-1-Cell-Derived M2 Macrophage Polarization by Producing 11,12- and 14,15-Epoxyeicosatrienoic Acid, Agonists of the PPARγ Receptor
Cho HY, Ahn SZ, Cho YS, Seo SK, Kim DH, Shin JG, Lee SJ · Pharmaceuticals(Basel). 16(4):593 / 2023.04 · 2023 cPMTb
- 341The impending impacts of large language models on medical education
Ahn SZ · Korean J Med Educ. 35(1):103-107 / 2023.03 · 2023 cPMTb
- 340Caenorhabditis elegans: a model organism in the toxicity assessment of environmental pollutants
Long NP, Kang JS, Kim HM · Environ Sci Pollut Res Int. 30(14):39273-39287 / 2023.03 · 2023 cPMTb
- 339Development of population pharmacokinetics model and Bayesian estimation of rifampicin exposure in Indonesian patients with tuberculosis
Soedarsono S, Jayanti RP, Mertaniasih NM, Kusmiati T, Permatasari A, Indrawanto DW, Charisma AN, Lius EE, Yuliwulandari R, Hoa PQ, Phat NK, Thu VTA, Anh NK, Ahn SZ, Long NP, Cho YS, Shin JG · Tuberculosis (Edinb). 139:102325 / 2023.03 · 2023 cPMTb
- 338Advancing personalized medicine for tuberculosis through the application of immune profiling
Thu VTA, Dat LD, Jayanti RP, Trinh HKT, Hung TM, Cho YS, Long NP, Shin JG · Front Cell Infect Microbiol. 10:13:1108155 / 2023.02 · 2023 cPMTb
- 337Comprehensive lipid profiles investigation reveals host metabolic and immune alterations during anti-tuberculosis treatment: Implications for therapeutic monitoring
Anh NK, Phat NK, Yen NTH, Jayanti RP, Thu VTA, Park YJ, Cho YS, Shin JG, Kim DH, Oh JY, Long NP · Biomed Pharmacother. 158:114187 / 2023.02 · 2023 cPMTb
- 336Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma
Jang YN, Cheong WY, Park GR, Kim YM, Ha JB, Ahn SZ · J Pers Med. 13(2):188 / 2023.01 · 2023 cPMTb